{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:39Z","timestamp":1788307239040,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.vaccine.2015.12.024","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:29:13Z","timestamp":1451348953000},"page":"714-722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children"],"prefix":"10.1016","volume":"34","author":[{"given":"Jorgen","family":"Stassijns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaatje","family":"Bollaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Baay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Verstraeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2015.12.024_bib0300","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.024_bib0305","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1586\/erv.12.35","article-title":"Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines","volume":"11","author":"Alving","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.2013.811188","article-title":"An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"49","key":"10.1016\/j.vaccine.2015.12.024_bib0315","first-page":"505","article-title":"Pandemic influenza A (H1N1) 2009 virus vaccine \u2013 conclusions and recommendations from the october 2009 meeting of the immunization Strategic Advisory Group of experts","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"issue":"49","key":"10.1016\/j.vaccine.2015.12.024_bib0320","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.12.024_bib0325","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.4161\/hv.7.12.18046","article-title":"Pooled analysis of safety data from pediatric Phase II RTS,S\/AS malaria candidate vaccine trials","volume":"7","author":"Vekemans","year":"2011","journal-title":"Hum Vaccines"},{"issue":"43","key":"10.1016\/j.vaccine.2015.12.024_bib0330","doi-asserted-by":"crossref","first-page":"7559","DOI":"10.1016\/j.vaccine.2011.08.016","article-title":"Safety of pandemic H1N1 vaccines in children and adolescents","volume":"29","author":"Wijnans","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2015.12.024_bib0335","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1750-2659.2011.00229.x","article-title":"Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis","volume":"5","author":"Yin","year":"2011","journal-title":"Influenza Other Respir Viruses"},{"issue":"9","key":"10.1016\/j.vaccine.2015.12.024_bib0340","doi-asserted-by":"crossref","first-page":"e24384","DOI":"10.1371\/journal.pone.0024384","article-title":"Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines","volume":"6","author":"Manzoli","year":"2011","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.vaccine.2015.12.024_bib0345","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1248\/yakushi.131.1733","article-title":"MF59 adjuvanted seasonal and pandemic influenza vaccines","volume":"131","author":"Tsai","year":"2011","journal-title":"Yakugaku zasshi: J Pharm Soc Jpn"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.024_bib0350","first-page":"208","article-title":"Assessment of the MF59-adjuvanted pandemic influenza A\/H1N1 vaccine. Systematic review of literature","volume":"79","author":"Ruiz-Aragon","year":"2013","journal-title":"An Pediatr (Barc, Spain)"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.024_bib0355","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.024_bib0360","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.024_bib0365","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-3156.2006.01754.x","article-title":"Safety and immunogenicity of the RTS,S\/AS02A candidate malaria vaccine in children aged 1\u20134 in Mozambique","volume":"12","author":"Macete","year":"2007","journal-title":"Trop Med Int Health"},{"issue":"32","key":"10.1016\/j.vaccine.2015.12.024_bib0370","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.vaccine.2005.03.019","article-title":"Safety and immunogenicty of RTS,S\/AS02A candidate malaria vaccine in Gambian children","volume":"23","author":"Bojang","year":"2005","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.024_bib0375","doi-asserted-by":"crossref","first-page":"e13838","DOI":"10.1371\/journal.pone.0013838","article-title":"Safety, immunogenicity and duration of protection of the RTS,S\/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I\/IIb trial","volume":"5","author":"Aide","year":"2010","journal-title":"PLoS ONE"},{"issue":"9598","key":"10.1016\/j.vaccine.2015.12.024_bib0380","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(07)61542-6","article-title":"Safety of the RTS,S\/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I\/IIb trial","volume":"370","author":"Aponte","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.024_bib0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1086\/600119","article-title":"Long-term safety and efficacy of the RTS,S\/AS02A malaria vaccine in Mozambican children","volume":"200","author":"Sacarlal","year":"2009","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.024_bib0390","doi-asserted-by":"crossref","first-page":"e14090","DOI":"10.1371\/journal.pone.0014090","article-title":"Safety of the malaria vaccine candidate, RTS,S\/AS01E in 5 to 17 month old Kenyan and Tanzanian Children","volume":"5","author":"Lusingu","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1475-2875-12-11","article-title":"Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S\/AS02(D) malaria vaccine in infants living in a malaria-endemic region","volume":"12","author":"Abdulla","year":"2013","journal-title":"Malar J"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0400","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/656190","article-title":"Evaluation of the safety and immunogenicity of the RTS,S\/AS01E malaria candidate vaccine when integrated in the expanded program of immunization","volume":"202","author":"Agnandji","year":"2010","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2015.12.024_bib0405","doi-asserted-by":"crossref","first-page":"e7302","DOI":"10.1371\/journal.pone.0007302","article-title":"Randomized controlled trial of RTS,S\/AS02D and RTS,S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children","volume":"4","author":"Owusu-Agyei","year":"2009","journal-title":"PLoS ONE"},{"issue":"20","key":"10.1016\/j.vaccine.2015.12.024_bib0410","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.vaccine.2015.12.024_bib0415","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0420","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","year":"2014","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.vaccine.2015.12.024_bib0425","doi-asserted-by":"crossref","first-page":"e9041","DOI":"10.1371\/journal.pone.0009041","article-title":"Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial","volume":"5","author":"Thera","year":"2010","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0430","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1371\/journal.pctr.0010032","article-title":"Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children","volume":"1","author":"Withers","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"11","key":"10.1016\/j.vaccine.2015.12.024_bib0435","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.024_bib0440","doi-asserted-by":"crossref","first-page":"e4708","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.024_bib0445","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.tube.2014.07.001","article-title":"Safety and immunogenicity of the M72\/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial","volume":"94","author":"Idoko","year":"2014","journal-title":"Tuberculosis (Edinb, Scotl)"},{"issue":"46","key":"10.1016\/j.vaccine.2015.12.024_bib0450","first-page":"1","volume":"14","author":"Waddington","year":"2010","journal-title":"Health Technol Assess (Winch, Engl)"},{"issue":"23","key":"10.1016\/j.vaccine.2015.12.024_bib0455","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2012.03.046","article-title":"Safety and immunogenicity of 2010\u20132011 H1N12009-containing trivalent inactivated influenza vaccine in children 12\u201359 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC\/CIHR Influenza Research Network (PCIRN) study","volume":"30","author":"Langley","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.024_bib0460","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and safety of H5N1 A\/Vietnam\/1194\/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2015.12.024_bib0465","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/irv.12295","article-title":"Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination","volume":"9","author":"Diez-Domingo","year":"2015","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.024_bib0470","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/infdis\/jiu173","article-title":"Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial","volume":"210","author":"Nolan","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0475","article-title":"Safety and immunogenicity of cell culture-derived A\/H3N2 variant influenza vaccines: a phase I randomized, observer-blind, dose-ranging study","author":"Johnson","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0480","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/INF.0b013e318257644f","article-title":"Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A\/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children","volume":"31","author":"Block","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2015.12.024_bib0485","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/INF.0b013e31824b9545","article-title":"Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A\/H1N1 influenza vaccine in children 3 to <9 years of age","volume":"31","author":"Nassim","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.024_bib0490","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4161\/hv.7.1.13411","article-title":"Assessment of the safety, tolerability and kinetics of the immune response to A\/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age","volume":"7","author":"Arguedas","year":"2011","journal-title":"Hum Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2015.12.024_bib0495","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/INF.0000000000000462","article-title":"Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A\/H1N1 pandemic influenza vaccine in children 6\u201335 months of age","volume":"33","author":"Knuf","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.024_bib0500","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2014.10.085","article-title":"Safety and immunogenicity of an MF59-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age","volume":"33","author":"Knuf","year":"2015","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.vaccine.2015.12.024_bib0505","doi-asserted-by":"crossref","first-page":"8696","DOI":"10.1016\/j.vaccine.2011.08.111","article-title":"Trivalent and quadrivalent MF59((R))-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study","volume":"29","author":"Della Cioppa","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0510","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/INF.0b013e31819d6394","article-title":"Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.vaccine.2015.12.024_bib0515","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3855\/jidc.4594","article-title":"Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children","volume":"8","author":"Solares","year":"2014","journal-title":"J Infect Dev Ctries"},{"issue":"1","key":"10.1016\/j.vaccine.2015.12.024_bib0520","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/INF.0000000000000465","article-title":"Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age","volume":"34","author":"Zedda","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"15","key":"10.1016\/j.vaccine.2015.12.024_bib0525","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N Engl J Med"},{"issue":"46","key":"10.1016\/j.vaccine.2015.12.024_bib0530","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2014.08.068","article-title":"Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children","volume":"32","author":"Nolan","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2015.12.024_bib0535","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"26","key":"10.1016\/j.vaccine.2015.12.024_bib0540","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.vaccine.2011.04.011","article-title":"Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents","volume":"29","author":"Garcia-Sicilia","year":"2011","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2015.12.024_bib0545","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/INF.0b013e31825e6cd6","article-title":"Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity","volume":"31","author":"Langley","year":"2012","journal-title":"Pediatr Infect Dis J"},{"issue":"45","key":"10.1016\/j.vaccine.2015.12.024_bib0550","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1016\/j.vaccine.2010.08.075","article-title":"Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0555","series-title":"Withdrawal assessment report, fluad pediatric influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C","author":"European Medicines Agency","year":"2013"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0560","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0565","series-title":"Twenty-second pandemic pharmacovigilance update. London","author":"European Medicines Agency","year":"2010"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.024_bib0570","doi-asserted-by":"crossref","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","article-title":"AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland","volume":"7","author":"Nohynek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0575","series-title":"Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation) Stockholm","author":"European Centre for Disease Prevention and Control","year":"2012"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.024_bib0580","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(13)70238-X","article-title":"Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action","volume":"14","author":"Barker","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.12.024_bib0585","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/hv.7.5.14821","article-title":"Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations","volume":"7","author":"Banzhoff","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2015.12.024_bib0590","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1136\/bmj.f2375","article-title":"Is the adjuvant solely to blame?","volume":"346","author":"Tsai","year":"2013","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1501796X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1501796X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T12:15:35Z","timestamp":1718280935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1501796X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0264410X1501796X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}